No Data
No Data
No Data
No Data
No Data
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating.
MT NewswiresApr 2 11:50 ET
Kyowa Kirin's Rare Disease Therapy Becomes World's Most Expensive Drug
Seeking AlphaMar 20 12:11 ET
13 Best Biotech Stocks To Buy Under $20
Yahoo FinanceMar 13 07:07 ET
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec
BenzingaMar 4 07:56 ET
UniQure Is Maintained at Neutral by Mizuho
UniQure Is Maintained at Neutral by Mizuho
Dow JonesMar 4 07:22 ET
Express News | Mizuho Maintains Neutral on UniQure, Lowers Price Target to $7
Moomoo 24/7Mar 4 07:12 ET
No Data
No Data